Proteomics and Cardiovascular Disease: An Update

Author(s): Alfonso Giovane, Francesco Paolo Mancini, Claudio Napoli, Maria Luisa Balestrieri

Journal Name: Current Medicinal Chemistry

Volume 15 , Issue 6 , 2008

Become EABM
Become Reviewer
Call for Editor


Proteomics has unraveled important questions in the biology of cardiovascular disease and holds even greater promise for the development of novel diagnostic and prognostic biomarkers. This approach may establish early detection strategies, and monitor responses to therapies. Technological advances (most notably blue native polyacrylamide gel electrophoresis, electrospray ionization, matrix- assisted laser desorption/ionization (MALDI), analysis of MALDI-derived peptides in Time-of-Flight (TOF) analyzers, and multidimensional protein identification technology (MudPIT) and bioinformatics for data handling and interpretation allow a large-scale identification of peptide sequence and post-translational modifications. Moreover, combination of proteomic biomarkers with clinical phenotype, metabolite changes, and genetic haplotype information is promising for the physician assessment of individual cardiovascular risk profile.

Keywords: mass spectrometry, two-dimensional gel electrophoresis, cardiovascular disease, Proteomics

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [555 - 572]
Pages: 18
DOI: 10.2174/092986708783769713
Price: $65

Article Metrics

PDF: 11